• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.

作者信息

Medisetty Mahender Kumar, Patel Atul, Pujari Sanjay

机构信息

Apollo Institute of Medical Science and Research, Apollo Health Campus, Hyderabad, India.

Department of Infectious Disease, Sterling Hospital, Ahmedabad, India.

出版信息

Int J Infect Dis. 2021 Apr;105:722. doi: 10.1016/j.ijid.2021.02.035. Epub 2021 Feb 15.

DOI:10.1016/j.ijid.2021.02.035
PMID:33601033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7883703/
Abstract
摘要

相似文献

1
Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.关于Udwadia等人所著的《口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻度至中度COVID-19中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验》致编辑的信
Int J Infect Dis. 2021 Apr;105:722. doi: 10.1016/j.ijid.2021.02.035. Epub 2021 Feb 15.
2
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.对Udwadia等人发表的文章《口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻至中度COVID-19中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验》所收到评论的回复
Int J Infect Dis. 2021 Apr;105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15.
3
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻至中度新型冠状病毒肺炎中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验
Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16.
4
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
5
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
6
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.法匹拉韦治疗新型冠状病毒肺炎患者的临床疗效与安全性
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.12.005. Epub 2020 Dec 7.
7
Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.印度医护人员使用法匹拉韦治疗 COVID-19 的真实世界经验。
J Assoc Physicians India. 2022 Dec;69(12):11-12.
8
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.法匹拉韦与COVID-19早期门诊治疗的必要性
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02489-20.
9
Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;19:1-13. DOI: 10.1080/03007995.2021.1920900.回复信：针对阿拉默·A、阿尔拉希德·AA、阿尔法菲·M等人的研究。与支持性治疗相比，法匹拉韦在中度至重度新冠肺炎患者中的有效性和安全性：一项倾向评分匹配敏感性分析的回顾性研究。《当前医学研究与观点》。2021年；19:1 - 13。DOI: 10.1080/03007995.2021.1920900
Curr Med Res Opin. 2022 Mar;38(3):355-356. doi: 10.1080/03007995.2021.2020463. Epub 2021 Dec 31.
10
Comment on: Favipiravir, an antiviral for COVID-19?关于：法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？的评论
J Antimicrob Chemother. 2021 Jan 1;76(1):279-280. doi: 10.1093/jac/dkaa378.

引用本文的文献

1
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.药物重新利用治疗新冠肺炎的疗效与安全性：2021年立场声明
Front Pharmacol. 2021 Jun 14;12:659577. doi: 10.3389/fphar.2021.659577. eCollection 2021.